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DEFINITIONS 
 
Conjugation   The chemical attachment of a chelator molecule to an           
    antibody. 
Immunoconjugate  The resultant adduct of conjugation 
Cold labeling  The tagging of a molecule with a non-radioactive isotope.  
Chelation   The complexing of a metal ion with a multi-dentate ligand. 
Cake The dry product in the vial on the completion of freeze  
 drying. 
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INTRODUCTION 
Background  
Therapeutic monoclonal antibodies (TMAs) continue to grow tremendously in their 
clinical importance since their first application more than thirty years ago (Ecker et al., 
2015). The oncological application of monoclonal antibodies has taken the same trend 
since the approval of the rituximab, the first approved TMA for cancer therapy 
(Reichert and Valge-Archer, 2007). Anti-tumor TMAs are particularly attractive for their 
high specificity in antigen binding. Therefore, they offer themselves as a clinically ef-
fective tool for targeting therapy to particular tumor cell types with minimal inhibition of 
non-target cells. Compared to the conventional small molecule anti-tumor agents, 
TMAs mechanism of tumor cytotoxicity is achieved through the activation of the im-
mune system in addition to the direct tumor cell inhibition. Indeed, the in vivo efficacy 
of the anti-tumor TMAs has been shown to be higher than for conventional small       
molecule therapeutic agents for some lymphoma types (Else et al., 2012). 
However, antibody therapy is not always effective. In some patient types, tumors may 
be refractory or resistant to TMAs or they may relapse. A number of strategies have 
been devised for the improvement of TMAs for such patient types. The approaches 
include, among others, the synthesis of antibody-drug conjugates and therapeutic ra-
dio-antibodies; some of these have already obtained regulatory approval for clinical 
application (Ujjani and Cheson, 2013). 
Thus, two radiolabeled TMAs have so far found approval for clinical application, ibri-
tumomab/90Y-ibritumomab tiuxetan and tositumomab/131I-tositumomab for the treat-
ment of refractory or relapsed low grade CD20+ Non-Hodgkin’s Lymphomas (NHLs). 
The benefit of using TMAs radiolabeled with energetic particle emitting radioisotopes 
for the targeted tumor treatment is the additional opportunity to kill other tumors cells 
in the vicinity of the CD20+ tumor cells through crossfire and bystander effects. The 
ability to kill non-CD20+ tumor cells is highly beneficial, especially where the tumor 
exhibits heterogeneity in antigen expression. The tissue range of the emitted particles, 
their therapeutic efficacy and also normal tissue toxicity depend on the energy of the 
particles, which in turn is dictated by the particular radioisotope used. 
A variety of suitable particle emitting radioisotopes is available for radiolabeling TMAs 
for the radioimmunotherapy (RIT) of tumors. These radioisotopes differ in terms of 
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their decay modes, half-lives, particle energies and chemistry. In the RIT of CD20+ 
NHL, products that have seen approval for clinical application have been radiolabeled 
with the beta-emitters; Yttrium-90 (ibritumomab/90Y-ibritumomab tiuxetan) (“Approval 
Letter - Ibritumomab Tiuxetan, (Zevalin), IDEC Pharmaceuticals Corp - 
ucm113489.pdf,” n.d.) and Iodine-131 (tositumomab/131I-tositumomab) (“Therapeutic 
Biologic Applications (BLA) > Bexxar Approval Letter 6/27/03,” n.d.). Other clinically 
useful radioisotopes include Lutetium-177, Re-188, Samarium-153, etc. Generally, 
radioisotopes emitting long tissue range beta particles may be more useful for large 
tumor masses, while low tissue range beta particle emitters may be more useful for 
small tumor masses, including small metastatic lesions. 
Radiolabeling of the TMAs can be achieved either directly or indirectly (Sugar et al., 
2014). The direct approach is feasible for radioiodination but it is unsuitable for most 
radiometal labeling work because TMAs lack strong chelating groups to strongly bind 
the radiometal cations. For clinical usefulness of a TMA based radiopharmaceutical, 
the in vivo thermodynamic and kinetic stability of the metal complex is vital. Hence, 
derivatization of the TMAs to introduce strong chelator groups is necessary. Chelator 
groups that are potentially useful for a variety of radiometals have already been    syn-
thesized and widely studied (Brechbiel, 2008). For trivalent radiometal cations such 
as lutetium or yttrium, the commonest are DOTA derivatives and DTPA derivatives. 
As an already available clinical example, derivatization of ibritumomab was done with 
tiuxetan for radiolabeling with yttrium-90 (Jacobs, 2007).  
All the currently approved RIT radiopharmaceuticals are formulated as liquid prepara-
tions. The challenges associated with such formulations are stability of the antibody in 
storage and a cumbersome radiolabeling process. The stability of antibodies in their 
low concentration solutions is low, hence their short shelf life and strict cold-chain 
transportation and storage. The cumbersome radiolabeling procedure increases the 
risk of mix-ups and poor quality of the injected preparation. For that reason, it is nec-
essary to produce a more stable preparation that is easier to radiolabel, preferably in 
a one-step process; it has a long shelf life in storage and does not require strict cold-
chain conditions during distribution. One strategy is to use the freeze drying technol-
ogy. 
Freeze drying is a widely applied, widely studied technology. It helps to produce dry 
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preparations of thermolabile drug substances with high porosity and fast dissolution 
during reconstitution. Its application in the production of biotechnological pharmaceu-
tical products is already well established (Ekenlebie et al., 2016). The freeze drying 
process removes almost all the water from the solution, thereby yielding a more stable 
product that weighs less, and is easy and fast to reconstitute.   
In our work, we intended to investigate the suitability of our freeze drying protocol for 
the preparation of a ready-to-use radiolabel freeze dried rituximab-1b4mDTPA kit   ra-
diopharmaceutical for radiolabeling with yttrium-90 or lutetium-177.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
LITERATURE REVIEW 
Non-Hodgkin’s lymphomas - NHL 
Lymphomas are a heterogeneous array of malignant tumors of the lymphoid system. 
They are broadly grouped into Hodgkin’s and Non-Hodgkin’s lymphomas. The NHLs 
are estimated to be the sixth most frequently diagnosed tumor types. Their incidence 
of 85% of the incidence of all lymphomas is much higher than that of HL (Siegel et al., 
2017).  
The NHLs are also a heterogeneous group of about 60 tumor types that can either be 
indolent or aggressive, the indolent being the commonest (Siegel et al., 2017). 
B cell lymphomas are more common than T cell lymphomas, accounting for about 
80% of all lymphomas. Specific tumor cell antigens distinguish between B-cell lym-
phomas and T cell lymphomas. Cell surface antigens that are specific for B-cells and 
commonly used clinically include CD20, CD79a and CD19 (Adams et al., 2009).  
CD20 is the most clinically important tumor marker for B cell lymphomas for the         
reason that, in addition to its being encountered in over 90% of all B cell NHLs (Del-
gado et al., 2003), it has also been successfully targeted for therapy of B cell lympho-
mas in over a million patients in about two decades (Boross and Leusen, 2012). CD20 
is a 35kDa B cell specific transmembrane glycosylated phosphoprotein. Its function is 
not known for certain, but it has been shown to act as a calcium ion channel. It has 
also been shown to participate in the regulation of B cell cycle progression and prolif-
eration.  
It is expressed by both tumor B cells and normal B cells. In normal B cells, CD20 
expression is dependent on the developmental stage of the B cells, starting from the 
pre-B cell all the way to mature B cells, but it is uncommon in plasma cells (Uchida et 
al., 2004).  
Treatment options and treatment responses of NHLs vary depending on the tumor 
type. Since almost all B cell NHLs are CD20+ (Delgado et al., 2003), antiCD20 TMAs 
are particularly useful. AntiCD20 TMA based medications that have been approved 
for therapy of lymphomas include rituximab, obinutuzumab, ibritumomab - 90Y and 
tositumomab – 131I. 
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Rituximab 
Rituximab is a type I anti-CD20 chimeric IgG 1 kappa TMA, bearing human derived 
constant regions and mouse derived variable regions. It has a molecular weight of 
143859.7Da and the molecular formula of C6416H9874N1688O1987S44.  
It is composed of two light chains of 213 amino acids each and two heavy chains with 
451 amino acids each as follows (DrugBank, 2016):  
 
Rituximab heavy chain chimeric 
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKGLEWIGAIYPGNGDTSYNQKFKGKATLT
ADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSK
STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSGLYSLSSVVTVPSSSLGTQTYICN
VNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIETISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGVSCSVMHEALHNHYTQKSLSLSPGK 
 
Rituximab light chain chimeric 
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASG
VPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAP
SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
             
 
Fig 1. Graphical representation of the structure of a monoclonal IgG antibody (Janda 
et al., 2016).  
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Figure 2. Proposed mechanism of action of rituximab. (Kasi et al., 2012) 
 
 
Rituximab is able to exert in vivo biological effects through a number of processes 
which are mainly antibody-dependent cell-mediated cytotoxicity (ADCC), comple-
ment-dependent cytotoxicity (CDC) and direct induction of apoptosis (Boross and 
Leusen, 2012). For its ADCC effect, the TMA binds to its specific CD20 antigen on the 
cell surface of the B tumor cell through its complementarity determining regions (CDR) 
within the variable regions, while its Fcγ region binds to and activates cytolytic immune 
cells such as natural killer (NK) cells, T cells, macrophages, etc. For the CDC process, 
which is a feature of type I antiCD20 TMAs, the antibody binding to the antigen causes 
the reorganization of lipid rafts on the cell membrane that activate complement, devel-
opment of membrane attack complex and cell lysis. Meanwhile, apoptosis results from 
the activation of the apoptosis pathways as an effect of the direct binding of the TMA 
to the CD20 antigen. 
 
Rituximab, the first FDA approved antiCD20 TMA, is applied today for the treatment 
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of B cell lymphomas alone or in combination with chemotherapy, radiotherapy or radi-
oimmunotherapeutic agents. Rituximab-based regimens are very effective for CD20+ 
lymphomas and cure rates of 50% are usually achieved for patients with some forms 
of aggressive NHLs (Johnston et al., 2010). For indolent types, responses to therapy 
are lower. Despite CD20 expression, some patients are either refractory or they re-
lapse following rituximab based regimens. Resistance to rituximab is currently esti-
mated to range from 30% to 60%, only less than a third of which have been found to 
have lost CD20 expression post rituximab therapy (Rezvani and Maloney, 2011). Such 
findings have necessitated the development of approaches geared towards improving 
therapeutic outcomes, including the development of new antiCD20 TMAs and radio-
immunotherapeutics. Radioimmunotherapeutics that have already been approved for 
lymphomas, especially indolent refractory or relapsed NHLs, are ibritumomab-90Y and 
tositumomab-131I. In clinical trials,  radioimmunotherapeutics showed much better ef-
ficacy and tolerability than immunotherapy alone (Witzig et al., 2002). 
 
Therapeutic radionuclides (Yttrium-90 and Lutetium-177) 
Since the first report of the beneficial effects of injected radio-radium in 1913, the array 
and application of particle emitting radioisotopes in clinical practice has grown tremen-
dously (Yeong et al., 2014).  
They are a group of diverse radionuclides with differing chemical and physical proper-
ties. Nonetheless, the common feature of therapeutic radionuclides is that they are 
particle emitters with a high linear energy transfer (LET).  
Currently, the most commonly used radionuclides are beta and alpha particle emitters. 
Examples of beta particle emitters are iodine-131, yttrium-90, and lutetium-90 while 
examples of alpha emitters are radium-223 and astatine-211.  
Table 1 below summarizes the most commonly encountered therapeutic radionuclides 
(Yeong et al., 2014). 
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Table 1.  Features of common clinically used therapeutic radionuclides (Yeong et al., 
2014), (Srivastava and Mausner, 2013) 
 
Radionuclide  Mode of 
decay 
Half-life E-max 
(MeV) 
Maximum 
soft tissue 
range (mm) 
Imageable  Gamma 
energy 
(keV) 
90Y β− 2.7d 2.3 11 No - 
177Lu β− 6.7d 0.5 1.7 Yes  208 
131I β−, γ 8.0d 0.6 2.4 Yes  364.5 
89Sr β− 50.5d 1.5 8.0 No - 
188Re β−, γ 17h 2.1 11 Yes  155 
186Re β−, γ 3.7d 1.1 3.2 Yes  137 
153Sm β−, γ 46.5h 0.8 3.1 Yes  103 
32P β− 14.3d 1.7 7.9 No  - 
 
 
The choice of the radionuclide to be used in the development of radiopharmaceuticals 
depends on the radionuclide’s availability and also on its physical properties, chemical 
properties and biological properties, all of which should be matched with the intended 
clinical use of the radiopharmaceutical. Physically, the       radionuclide should have a 
high yield of particle radiations of appropriate energy. The half-life, especially for anti-
body-based radiopharmaceuticals, should be matched appropriately with the in vivo 
pharmacokinetics of the targeting antibody. Since the biological half-life of many TMAs 
is about three days, it is desirable that therapeutic radionuclides for radiolabeling 
TMAs should have physical half-lives of about three to seven days. Shorter lived ones 
may not allow for sufficient accumulation of radioactivity at the tumor site, while a too 
long half-life may expose patients to   excessive radiation doses apart from their lower 
efficacy. Ideally, therapeutic                           radionuclides should be devoid of non-
particulate radiation. However, the concurrent emission of suitable energy gamma 
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rays is in fact a desired feature of ‘ideal’ theranostic radionuclides since it facilitates 
dosimetry and monitoring of the therapy. The emitted particles must also be of suitable 
energy. If the energy is too high, toxicity to non-target tissues is likely to be higher than 
acceptable, whereas low energy particles are likely to be ineffective. Alpha particles 
are of high energy, but since their tissue range is very low, their LET is very high and 
suitable for treating tumor micro-metastases. On the other hand, beta particles have 
variable energies and the high energy betas are more penetrating but with low LET. 
For that reason, radioisotopes that emit high energy betas are suitable for targeting 
large tumor masses. Since lower energy betas have very high LET and low tissue 
range, they are more suitable for targeting tumor micro-metastases than large tumor 
masses. In addition to the above is the requirement for a suitable chemistry of the 
radionuclide. The chemical properties of the radioisotope should permit a fast, strong 
and kinetically stable attachment of the radionuclide to the targeting molecule. Of 
equal importance is the availability of the radioisotope. A radioisotope that is too diffi-
cult to obtain in adequate amounts is unlikely to be of any appreciable benefit to patient 
care. 
Yttrium is a group III element with atomic number 39 and electronic configuration of 
[Kr] 4d1 5s2. The clinically important therapeutic radioisotope is Yttrium-90. Yttrium-90 
decays 100% by emitting beta particles to zirconium-90 in a half-life of 2.67 days (MM 
Be, 2004). Its beta particles have a maximum energy of about 2.3 MeV and their     
maximum tissue penetration is 11mm, as shown in Table 1 above. The chemistry of 
yttrium is similar to that of the lanthanides, which is dominated by its +3 oxidation state. 
It forms complexes that are highly stable, both thermodynamically and kinetically, with 
multi-dentate ligands containing hard donor ligands such as amine groups and car-
boxylate groups. Examples of the chelators are shown in Table 2 below. Yttrium-90 is 
commercially available mostly from strontium-90/yttrium-90 generators and also from 
neutron irradiation of yttrium-89 (Be MM, 2004).  
The production and purification of the radionuclide is done at the radionuclide suppli-
ers’ premises and availed to the compounding radiopharmacies as 90YCl3. Yttrium-90 
is already used today in ibritumomab-tiuxetan-90Y for the therapy of indolent                   
refractory or relapsed NHL and also for radioembolization with microspheres for ther-
apy of   hepatocellular tumors (Davies, 2007) (Bhangoo et al., 2015). 
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Lutetium is a lanthanide element, with atomic number 71 and electronic configuration 
of [Xe] 4f145d16s2. Lutetium-177 is the commonest applied lutetium radioisotope for 
internal dose radiotherapy. It decays 100% through beta emission to hafnium-177, in 
a half-life of 6.65 days (MM Be 2004 Vol. 2-A= 151 to 242). The beta particles of 
lutetium-177 have maximum energy of 497.8 keV and a maximum tissue range of 1.7 
mm, as shown in Table 1 above. Like other lanthanides, the chemistry of lutetium is 
dominated by its +3 oxidation state. Its stable complexes are those with   multi-dentate 
ligands composed of hard donor ligands such as amine groups and carboxylate 
groups, in which its coordination numbers range from 6 to 9 (L. Parus et al., 2015). 
Examples of chelators that are useful in the radiopharmaceutical chemistry of lutetium 
are given in Table 2 below. Lutetium-177 is produced in nuclear reactors by neutron 
irradiation of lutetium-176 or from the neutron irradiation of ytterbium176 followed by 
beta decay of the resultant ytterbium-177 MM Be 2004 Vol. 2-A= 151 to 242). It is 
supplied to radiopharmacies as 177LuCl3. Lutetium-177 is currently applied in 177Lu-
DOTATATE for therapy of somatostatin receptor (SSTR) overexpressing neuroendo-
crine tumors (NET) (Strosberg et al., 2017). 
 
Radiolabeling of antibodies 
The radiolabeling of antibodies can be achieved either directly or indirectly depending 
on the chemistry of the radioisotopes (Tolmachev et al., 2014). The direct radiolabeling 
approach is suitable for radionuclides whose chemistry allows them to be bonded di-
rectly and strongly to the amino acid residues on the antibody molecules.  
Radiohalogenation is a classic example of this. Direct radioiodination has been em-
ployed successfully for the production of therapeutic radioimmunopharmaceuticals 
such as tositumomab-131I. Attractive as it is, direct radiolabeling of antibodies is not 
always feasible, especially for labeling with most radiometals. Usually, antibodies lack 
the suitable arrangement of donor groups for strong chelation with radiometals. For 
that reason, the indirect radiolabeling method is used, which requires derivatization of 
the antibodies with suitable bifunctional chelator (BFC) molecules either before or dur-
ing the radiolabeling process. There are two ways the indirect approach can be ef-
fected; one is the pre-labeling method and the other is the post-labeling method (Liu, 
2008). In the pre-labeling method, the radiometal is chelated with the BFC and the 
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resultant chelate is conjugated to the antibody via reactive groups on the amino acid 
residues. The advantage of this method is that it is less aggressive on the antibody 
structure since it avoids exposing the antibody to the harsh conditions of chelation 
chemistry. However, it is difficult to implement radiopharmaceutical kit formulation with 
this method. Therefore, the post-labeling method became more attractive and more 
popular due to the desire to produce ready-to-label kit radiopharmaceuticals. In this 
post-labeling method, the antibody is first conjugated with the BFC, purified and then 
mixed with the radiometal to effect the radiolabeling. This method is currently used for 
the production of ibritumomab-90Y, which is supplied as a liquid kit radiopharmaceuti-
cal where ibritumomab is already conjugated with tiuxetan, ready to radiolabel by mix-
ing with 90YCl3 solution (“Zevalin_Package_Insert.pdf,” n.d.). 
In view of the foregoing, the growing importance of BFCs in radiopharmaceutical pro-
duction cannot be overemphasized. Depending on the functional groups on BFC, the 
conjugation amino acid residues on the antibody molecules will vary. The commonest 
employed BFCs are designed to attach covalently through amide or thioamide bond 
formation with the epsilon primary amino groups of lysine residues (Sugiura et al., 
2014). Since the charge of the free amine groups may be vital for the antibody function, 
the conjugation at these groups needs to be carefully crafted. Also, a large number of 
BFC groups may alter the antibodies’ CDRs steric fitting onto the antigen binding sites. 
On the other hand, fewer than optimal BFCs may decrease the specific activity of the 
radiopharmaceutical with consequent decrease in therapeutic efficacy. In addition to 
the above concerns, the chemically altered antibody may have significantly different 
in vivo pharmacokinetics from the parent antibody. It is therefore necessary to evalu-
ate the TMA based radiopharmaceutical from physicochemical properties, in vitro an-
tigen binding studies to in vivo studies because the assumption that the radiopharma-
ceuticals’ pharmacokinetics would be similar to those of the      parent antibody is not 
always accurate.  
Below is a list of the commonly encountered BFCs for radiolabeling in yttrium and 
lutetium based radiopharmaceuticals (Brechbiel, 2008).  
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Table 2. Commonly used bifunctional chelating agents (L. Parus et al., 2015)  
Structure  Name  Acyclic/cyclic 
 
DOTA Cyclic  
 
DOTA-NHS ester Cyclic  
 
p-SCN-Bn-DOTA Cyclic  
 
NOTA Cyclic  
 
p-SCN-Bn-NOTA Cyclic  
 
p-SCN-Bn-1B-DTPA Acyclic  
 
p-SCN-Bn-1B4M-
DTPA 
Acyclic  
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Freeze drying  
Freeze drying is the process of removing water from a product mainly through subli-
mation. The technology is very useful for the drying of thermolabile drug   substances, 
for example protein-based and biotechnological products. Water can   promote the 
hydrolysis of biotechnological and protein based drug substances, especially dilute 
solutions, thereby shortening the products shelf life. In their dry state, however, these 
drug products are less bulky, more stable and they can be transported and stored at 
higher temperatures. Their shelf lives can also be extended significantly. The cycle of 
freeze drying follows three main steps: freezing, primary drying and secondary drying. 
The quality of a freeze dried product depends heavily on the efficiency of the freeze 
drying process.  
In the freezing step, the aqueous product is cooled to temperatures and for durations 
that ensure a complete conversion of the product to solid. As the temperatures are 
lowered, it reaches a point where ice nucleation starts randomly within the solution. 
As the ice crystals grow with further cooling, the water separates (as ice) from the 
unfrozen product, which becomes increasingly saturated and is called a freeze con-
centrate. On further cooling, the freeze concentrate turns viscous and later glassy at 
the glass transition temperature. Freezing is conducted at much lower temperatures 
than the glass transition temperature. The freezing is required to occur uniformly 
throughout the formulation so as to yield a dry product with uniform pore size and other 
parameters. An annealing step can be introduced so as to facilitate uniform freezing. 
Annealing step involves elevating the temperature of the frozen sample, holding it at 
the annealing temperature and then lowering it back to the freezing temperature to 
continue with the freezing step. Annealing has been shown to facilitate faster, com-
plete uniform freezing (Abdelwahed et al., 2006) (Chouvenc et al., 2006). The anneal-
ing temperature is usually below or at the glass transition temperature of the formula-
tion. The temperature at which the viscous matrix turns back to free-flowing liquid on 
reheating is the melt or collapse temperature. The temperatures are unique for differ-
ent formulations. For efficient freeze drying, it is important for these temperatures to 
be known for the particular formulations being freeze dried. Knowledge of these tem-
peratures informs the decision on the primary drying temperature because even 
though primary drying has been successfully performed at or slightly above the glass 
24 
transition temperature, it should not be performed at or above the collapse tempera-
ture. The freezing rate has major implications on the product characteristics (Lee and 
Cheng, 2006), such as pore size, final moisture content etc, and also to the required 
drying time. 
The primary drying step requires input of heat energy into the product so as to                
facilitate sublimation. It is usually the longest phase of the freeze drying process. The 
sublimation of the ice causes increased water vapor partial pressure within the  drying 
chamber. For the drying step to proceed efficiently, the liberated water vapor must be 
extracted from the drying chamber since the driving force for the drying process is the 
water vapor partial pressure gradient between the drying chamber and the immediate 
environment. As the product becomes drier, so increases the collapse temperature 
such that secondary step drying can be done at even higher temperatures. 
At the end of primary drying, residual sorbed (bound) moisture of about 5-10% w/w 
remains (Patel et al., 2010). During the secondary drying step, the bound moisture is 
removed by desorption. If primary drying is done well enough, the secondary drying 
can be performed at room temperature depending on the collapse temperature of the 
formulation. The desired final moisture content after secondary drying varies from one 
drug substance to another. Proteinaceous substances generally require higher final 
moisture content than small molecular substances. Too high moisture content yields 
a poor stability product while too low moisture content causes structural, and hence 
functional, damage to the protein-based substances. Excessively dehydrated protein-
based substances tend to have higher opalescence and longer reconstitution times 
on reconstitution. Generally, protein-based substances can be dried to moisture con-
tent of 1% – 3% w/w (Schneid et al., 2011).  
For a successful freeze drying, critical formulation characteristics and critical process 
parameters must be identified and controlled. One critical formulation characteristic is 
the collapse temperature. The desire is to have a formulation with as high a                   
collapse temperature as possible. Freeze drying is an expensive process in terms of 
electrical power consumption. A higher collapse temperature allows for the freezing 
and primary drying phases to be done not only at higher temperatures, but also for 
shorter times and more effectively. Since the freeze drying process is highly stressful 
to the drug substances, especially proteins, it is desirable also that the process takes 
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as short a time as possible. One method to influence the collapse temperature of a 
formulation is to incorporate carefully selected excipients. 
Excipients can have a profound effect on the freeze drying process. Excipients used 
in freeze drying include buffers, tonicity modifiers, bulking agents, surfactants,            
cryoprotectants, lyoprotectants, modifiers of collapse temperature, antioxidants, etc. 
For radiopharmaceutical products, however, the target is to incorporate as few as nec-
essary excipients. The choice of the excipients relies on their necessity and their com-
patibility with the radioisotope label. Especially for kit radiopharmaceuticals for radio-
labeling with radiometals, it is vital to ensure that none of the excipients binds the 
radioisotope.  
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MATERIALS AND METHODS 
Materials 
1. Orbital shaker, MRC 
2. Falcon 15ml conical centrifuge tubes 
3. Ultracel® - 30K, Millipore, Ireland  
4. Labconco Free Zone Stoppering Tray Dryer, (USA)  
5. Oakton Acorn pH 6 Meter 
6. Medical Fridge, Liebherr LKv 3913  
7. Laminar flow cabinet, Miniflo Due type 120 
8. Jenway UV/VIS spectrophotometer 6715 
9. Phosphate buffer 0.1M, pH 8.0 
10. Rituximab 500mg/50ml, Mabthera®, Roche Co, CA, USA, 
11. Ammonium Acetate 50mM buffer pH 5.5 
12. Gel filtration 10mL Sephadex-25G columns 
13. Yttrium chloride powder, Sigma 
14. Lutetium chloride powder, Sigma 
15. 1b4m-DTPA powder, Sigma 
16. FTIR Spectrometer, PARAGON 1000, Perkin Elmer 
17. Raman Spectrometer, Horiba JobinYvon LabRam 300 Infinity, with Olympus 
MPlanN confocal microscope. 
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Methods  
Purification of rituximab from MabThera® 
2ml of the commercial product (MabThera®) was loaded into Amicon 2ml 30kDa         
ultrafilters and ultrafiltered at 5000 rpm in 4 cycles of one hour per cycle at 2-8°C. 2ml 
of 0.1M phosphate buffer pH 8.0 was added to the ultrafilter at the end of every cycle. 
The ultrafiltrate was discarded. After the 4th cycle, the purified rituximab was recovered 
by reverse filtration at 5000rpm for one hour. The product was reconstituted to 2ml 
with 0.1M pH 8.0 phosphate buffer and stored at 2-8°C temperatures in 15ml falcon 
conical centrifuge tubes. 
Freeze drying of rituximab 
Samples of rituximab formulations were freeze dried, some using the already                
established three day protocol and others using the new two-day protocol. 
For the three-day protocol, 1ml aliquots of purified 1mg/ml rituximab in 0.1M phos-
phate buffer pH 8.0 were dispensed into 10ml type 1 glass vials at 2-8°C. The vials 
were partially closed with the lyophilization metal-free rubber stoppers and loaded into 
the freeze drier at shelf temperature of 4°C. The shelf temperature was then lowered 
at a rate of 0.4°C/min to -40°C. It was held at -40°C for 3 hours and an annealing step 
was added for the freezing phase to complete in 10 hours before the vacuum pump 
was turned on. During the annealing, the shelf temperature was raised at a rate of 
0.2°C/min to -15°C, held for 5h and then lowered back to -40°C at the same rate. The 
subsequent phases were performed at chamber pressures of 0.12mBar. At a rate of 
0.2°C/min, the shelf temperature was raised to -10°C and held at the -10°C for 25 
hours for the primary drying phase. At the end of the primary drying phase, the shelf 
temperature was elevated at a rate of 0.4°C/min to 25°C and held at the 25°C for 11 
hours for the secondary drying phase.  After the secondary drying phase, the chamber 
vacuum was released with atmospheric air. The vials were then automatically         
stoppered and stored at 2-8°C pending further investigations. 
For the two day protocol, 1ml aliquots of purified 1mg/ml rituximab in 0.1M  phosphate 
buffer pH 8.0 were dispensed into 10ml type 1 glass vials at 2-8°C. The vials were 
partially closed with the lyophilization metal-free rubber stoppers and loaded into the 
freeze drier at a shelf temperature of 4°C. The shelf temperature was then maintained 
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at 4°C for 30min. Then, it was lowered at a rate of 1°C/min to -40°C, held for 5 hours 
for the freezing phase before the vacuum pump was turned on. The subsequent 
phases were performed at chamber pressures of 0.12mBar. At a rate of 0.15°C/min, 
the shelf temperature was raised to -10°C and held at the -10°C for 15 hours for the 
primary drying phase.  
At the end of the primary drying phase, the shelf temperature was elevated at a rate 
of 0.2°C/min to 25°C and held at the 25°C for 11 hours for the secondary drying phase.  
At the end of secondary drying, the chamber vacuum was released with atmospheric 
air. The vials were stoppered and stored at 2-8°C pending further investigations. 
Conjugation 
2ml of the rituximab purified product was pipetted into a 15ml Falcon centrifugation 
tube, into which 1.54mg in 0.154ml of 1b4mDTPA in 0.1M phosphate buffer pH 8.0 
was added to make a rituximab-to-1b4mDTPA mole ratio of 1:20. The mixture was 
then mounted on an orbital shaker in 2-8°C and left to react overnight (for 18 hours) 
at shaker speed of 50rpm. 
Purification of immunoconjugate 
The reaction mixture was loaded onto 2ml Amicon 30kDa ultrafilters and ultra-filtered 
at 5000 rpm in 2-8°C for 4 one-hour cycles, washing with 2ml of 0.1M pH 8.0           
phosphate buffer in each cycle. After every cycle, the absorbance of ultrafiltrate at 
280nm wavelength in a uv-vis spectrophotometer was determined and the ultrafiltra-
tion   continued until the ultrafiltrate absorbance was zero (after the 4th cycle).  
The purified immunoconjugate was recovered from the ultrafilters by reversing the        
ultrafilters and centrifuging at 500rpm for one hour.  
Concentration determination by UV-VIS spectrophotometry 
The purified immunoconjugate was reconstituted to 1ml using 0.1M phosphate buffer 
pH 8.0. An aliquot of 0.100ml was drawn therefrom, reconstituted to 1ml with 0.1M 
phosphate buffer pH 8.0 and its concentration determined using UV-VIS spectropho-
tometry at 280nm wavelength.  
Freeze drying of the immunoconjugate 
Freeze drying of the immunoconjugate was performed using the two-day freeze drying 
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protocol as described under freeze drying of rituximab above. 
‘Cold’ labeling and purification of ‘cold-labeled product 
Two vials were used for chelating, one vial for chelation with stable Lutetium and the 
other for chelation with stable Yttrium. One of the vials was reconstituted with 1ml 
0.05M acetate buffer pH 7.0 for chelation with stable Lutetium. The other vial was 
reconstituted with 1ml 0.05M acetate buffer pH 5.5 for chelation with stable Yttrium. 
A 10 mL solution of LuCl3 1.0709mg/ml in 0.05M HCl (Solution A) was prepared. A 
100mcl solution of YCl3 11.555mg/ml (that is 5.7775mg in 50mcl) in 0.05M HCl (So-
lution B) was also prepared. A 10ml solution of EDTA 0.01M in metal-free distilled 
water was prepared and its pH adjusted to 6.0 (Solution C).  
10mcl of solution A was added and into one of the vial containing 1mg rituximab-
1b4mDTPA immuno-conjugate reconstituted with 0.05M acetate buffer pH 5.5. The 
reaction mixture was incubated at room temperature for 30min (Mixture I). , 61mcl of 
Solution C was added into Mixture I and incubated for 15min at room temperature. 
Then, the mixture was purified by washing through a 10ml G25 Sephadex column with 
phosphate buffer pH 8.0 into 1ml fractions. High concentration fractions (fractions 4 
and 5) were collected and the rest was discarded. The purified product was stored in 
type I glass vials in refrigerator pending further manipulation. 
Into the other vial containing 1mg of rituximab-1b4mDTPA immuno-conjugate               
reconstituted with 0.05M acetate buffer pH 5.5, 30mcl of Solution B was added and 
mixed. The reaction mixture was incubated at room temperature for 30min (Mixture 
II).  
Then 63mcl of Solution D was added into Mixture II, mixed and incubated at room 
temperature for 15min. Then, the mixture was purified by washing through a 10ml G25 
Sephadex column with phosphate buffer pH 8.0 into 1ml fractions. High concentration 
fractions (fractions 4 and 5) were collected and the rest was discarded. The purified 
product was stored in type I glass vials in refrigerator pending further manipulation. 
Analysis 
1. Fourier Transform Infrared (FTIR) spectroscopy 
For this investigation, both solid and liquid samples were investigated. Firstly,                
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investigations were made on the rituximab commercial product (MabThera®),            
purified non-freeze dried rituximab, non-freeze dried immunoconjugate of 1b4mDTPA, 
yttrium chelated non-freeze dried immunoconjugate and lutetium chelated non-freeze 
dried immunoconjugate. Secondly, investigations were made on the freeze dried ritux-
imab, freeze dried immunoconjugate, yttrium chelated freeze dried immunoconjugate 
and lutetium chelated freeze dried immunoconjugate. 
Liquid samples 
The investigated liquid samples were of rituximab commercial product, purified       
rituximab, freeze dried rituximab from 3-day freeze drying protocol, freeze dried     
rituximab from 2-day freeze drying protocol, non-freeze dried immunoconjugate, 2-day 
freeze dried immunoconjugate, yttrium chelated freeze dried immunoconjugate, yt-
trium chelated non-freeze dried immunoconjugate, lutetium chelated freeze dried im-
munoconjugate and lutetium chelated non-freeze dried immunoconjugate. The freeze 
dried rituximab and freeze dried immunoconjugate were reconstituted with 1ml 0.9% 
saline solution for the investigation while the purified rituximab, non-freeze dried im-
munoconjugate, yttrium chelated immunoconjugates and lutetium chelated  immuno-
conjugates were investigated as solutions in 0.1M phosphate buffer pH 8.0. 
A background scan was taken on an empty crystal surface. Then, a drop from the 
products was drawn with spatula and applied onto the mounting plate so as to cover 
the crystal surface of the ATR-FTIR spectrometer and scanned with wavenumber 
range of 4000 – 800 cm-1. The mounting plate was cleaned with an alcohol swab prior 
to scanning of subsequent samples. 
Solid samples 
The investigated solid samples were of freeze dried rituximab via the 3-day protocol, 
freeze dried rituximab via the 2-day protocol and freeze dried immunoconjugate.  
A background scan was run on an empty crystal surface. Then, a small but enough 
amount of the solid powder was applied onto the mounting plate as to cover the        
crystal surface. The pressure knob was placed on top of the sample and screwed until 
it double-clicked into position. Scanning was done at wavenumber range of 4000 – 
800 cm-1. The mounting plate was cleaned with alcohol swab.  
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RESULTS 
 
Purification of rituximab from commercial product MabThera® 
Rituximab used in my work was obtained from the commercial product MabThera®. 
Because this commercial product was dedicated for application in patients    it con-
tained some additives and stabilizer. For the realization of our experiments we needed 
the pure antibody. For that reason, we purified the commercial product using ultrafil-
tration. 
During the process of ultrafiltration as it is described in methods, we wanted to         
eliminate all other substances and fragments of the antibody obtained during the pro-
cess of ultrafiltration.  
We used Size exclusion chromatography (SEC) to confirm the purity and presence of 
the whole rituximab as shown in Fig. 3 and 4 below.  
 
 
Figure 3. Size exclusion chromatography with UV-VIS detection for purified rituximab 
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Figure 4. Comparison of the Size exclusion chromatography spectra for non-purified 
and purified rituximab solution. 
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Freeze drying of the antibody to determine a suitable protocol 
The freeze drying protocol that we wanted to use was the key point of our                        
investigation because many authors already used this method for preparing the kit 
containing rituximab (Park et al., 2012) (Gjorgieva Ackova et al., 2014). Gjorgieva 
Ackova et al. used the protocol of 3 days (highlighted in Fig. 5 below) as a suitable 
protocol for preparing the same kit (Gjorgieva Ackova et al., 2014).  
In my work I wanted to compare their three-day protocol with a new two-day protocol 
that I expect would offer faster freeze drying, similar stability of the final product, similar 
quality and labeling yield. 
As we can see from the figures 5 and 6, the differences in the two protocols are that 
the two-day protocol is devoid of the annealing step and the ramping times. 
Table 3. 3-day freeze drying cycle 
Segment  Freezing temperature  RAMP(Speed) Holding Time  
1 (Pre-freezing) Room Temp to 40C 0.40C/min 30 minutes 
2 (Freezing)  40C to -450C 0.40C/min 3 hours  
-450C to -150C 0.150C/min 6 hours 
-150C to -450C 0.20C/min 2 hours  
3 (Primary Drying) -450C to -100c 0.150C/minute 28 hours  
4 (Secondary Drying)  -100C to 250c 0.150C/minute 14 hours  
 
Table 4. 2-day freeze drying cycle 
Segment  Freezing temperature  RAMP(Speed) Holding Time  
1 (Pre-freezing) Room Temp to 40C 1.00C/min 30 minutes 
2 (Freezing)  40C to -450C 1.00C/min 5 hours   
3 (Primary Drying) -450C to -100c 0.150C/minute 28 hours  
4 (Secondary Drying)  -100C to 250c 0.20C/minute 14 hours  
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Fig. 5. Graphic scheme of the three-day freeze drying protocol 
 
 
Fig. 6. Graphic scheme for the two-day freeze drying protocol 
 
After freeze drying we compared the size and appearance of the obtained “cake” of 
the final product. As we can see from the Figure 7 below, the cake is looking more 
consistent and contracted. 
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Fig. 7. Freeze dried rituximab cake products for the two-day and the three-day freeze 
drying protocols 
 
Table 5: Average reconstitution times of freeze-dried rituximab products 
Product  Reconstitution time (seconds) 
3-day protocol 77.86 
2-day protocol 68.38 
 
As is visible from Figure 8 below, the solution of the products of three days and two 
days freeze drying protocols has similar clarity on visual inspection.  
 
Fig. 8. Clarity of the reconstituted products of the two-day and the three-day freeze 
drying protocols 
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The reconstituted freeze dried immunoconjugates were tested using SEC to see if 
there was destruction of the complex after freeze drying. As seen from the SEC spec-
tra in Figure 9 below, the peak of the product from the three-day protocol was broader 
(encompassing fraction numbers 4,5,6,7) than the peak obtained from the product of 
the two-day freeze drying protocol (contributed by fractions 4,5,6). 
 
    
 
Fig. 9. Comparison the SEC spectra of rituximab from the three-day and the two-day 
freeze drying protocols 
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Fig. 10. Comparison between the SEC spectra of the rituximab in the commercial 
(MabThera®) product and the SEC spectra for freeze-dried rituximab products from  
different freeze drying protocols 
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Conjugation of rituximab with 1b4m-DTPA  
The process of conjugation as described in the methods section above, was performed 
using the ligand 1b4mDTPA in 0.1M phosphate buffer pH 8.0 added to the purified 
antibody. The ratio of the antibody and ligand in the mixture of the complex rituximab-
to-1b4mDTPA was 1:20. After the incubation period, the immunoconjugate mixture 
containing rituximab-1b4mDTPA was purified. 
Purification of immunoconjugate 
We used the same method of ultrafiltration for the purification of the immunoconjugate 
as we used for the antibody, as a more convenient method that does not necessarily 
damage the antibody. 
 
 
Fig. 11. SEC spectrum of a sample of the non-purified conjugation mixture 
 
As we can see from Figure 11 above, the immunoconjugate rituximab-to-1b4mDTPA 
is the biggest of the multiple present peaks. After purification, as shown in Figure 12 
below, the smaller peaks were eliminated, demonstrating the effectiveness of the pu-
rification process. 
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Fig. 12. SEC spectrum with UV-VIS detection for the purified immunoconjugate. 
 
Concentration determination by UV-VIS spectrophotometry 
After purification, we determined the concentration of the purified immunoconjugate 
as described in the methods section above. Then, the bulk immunoconjugate was   
reconstituted with 0.1M phosphate buffer pH 8.0 into a 13.7ml solution of 1mg/ml and 
stored at 2-8°C in a 15ml falcon conical centrifuge tube. 
The purified immunoconjugate was used to prepare the freeze dried kit radio-             
pharmaceutical. 
 
Freeze drying of the rituximab-1b4mDTPA immunoconjugate 
For the freeze drying of the immunoconjugates we used the two days protocol that we 
had tested with rituximab. Its schema is depicted in Fig. 6 above. The cake is as shown 
in Figure 13. below. 
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Fig. 13. Cake products of the freeze dried immunoconjugate 
 
The freeze drying process normally reflects on the quality of the solution after the                
reconstruction of the freeze dried product. We did the reconstitution of the freeze dried 
product with 0.9% saline solution and the solution is as shown in Figure 14 below. 
Reconstitution time for the rituximab-1b4m immunoconjugate was 30.88 seconds. 
 
 Fig. 14. Solution of reconstituted freeze dried immunoconjugate  
‘Cold’ labeling and purification of ‘cold’-labeled product 
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Cold labeling was performed using 175Lu or 89Y as described in the methods       section 
above. The goal of cold labeling was to use the same moles of the Lu or Y as they are 
clinically used with their respective radioisotopes in their recommended maximum 
therapeutic activities.  
The calculated amount of 175Lu used per 1mg of immunoconjugate was 1.061mcg and 
the amount of 89Y used per 1mg of immunoconjugate was 0.0589mcg.  
The chelation process is a stressful process to the immunoconjugate, in which case 
the immunoconjugate is expected to degrade to some extent. Sometimes, the          
chelation process is stressful enough to induce significant damage to the immunocon-
jugate.  
It is, therefore, prudent to monitor this critical process. In our case, we investigated 
this by running SEC on a sample of the chelate for the purpose of informing us ofthe 
need for post labeling purification.  
The expected outcome was demonstrated in the SEC spectrum as shown in Figures 
15 and 16 below. 
 
Fig. 15. Size exclusion chromatography for the chelation mixture of immunoconjugate 
with yttrium 
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Fig. 16. Size exclusion chromatography for the chelation mixture with lutetium 
 
Qualitative investigations by Fourier transform infrared (FTIR) spectroscopy 
FTIR is a very useful technique for studying the molecular structural integrity of a     
protein in liquid formulations and also in solid formulations.  
For our experiment, the FTIR spectra were obtained using the procedure described in 
the methods section above. 
Using this technique, we studied: 
- three days freeze dried rituximab,  
- two days freeze dried rituximab,  
- two days freeze dried rituximab-1b4m immunoconjugate,  
- non-freeze dried rituximab commercial product,  
- non-freeze dried rituximab-1b4mDTPA immunoconjugate,  
- lutetium chelated non-freeze dried rituximab-1b4m-DTPA,  
- yttrium chelated non-freeze dried rituximab-1b4m-DTPA,  
- 0.9% saline solution of two days freeze dried rituximab-1b4mDTPA,  
- ultra-filtered non-freeze dried rituximab-1b4m DTPA solution,  
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- lutetium chelated freeze dried rituximab-1b4mDTPA solution and     
- yttrium chelated freeze dried rituximab-1b4mDTPA solution.  
Solid samples 
 
 
Fig. 17. ATR/FTIR spectrum for the three-day freeze dried rituximab product 
 
 
Fig. 18. ATR/FTIR spectrum for the two-day freeze dried rituximab product 
 
 
44 
 
Fig. 19. ATR/FTIR spectrum for the powder two-day freeze dried rituximab-
1b4mDTPA immunoconjugate 
 
 
 
Liquid samples 
 
 
 
Fig. 20. ATR/FTIR spectrum for the non-freeze dried commercial rituximab liquid   
product 
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Fig. 21. ATR/FTIR spectrum of the solution of the non-freeze dried rituximab-
1b4mDTPA immunoconjugate 
 
 
Fig. 22. ATR/FTIR spectroscopy of the lutetium chelated non-freeze dried rituximab-
1b4m-DTPA 
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Fig. 23. ATR/FTIR spectroscopy of the yttrium chelated non-freeze dried rituximabq-
1b4m-DTPA 
 
 
Fig. 24. ATR/FTIR spectrum for the solution of two-days freeze dried rituximab-
1b4mDTPA 
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Fig. 25. ATR/FTIR spectrum for the ultra-filtered non-freeze dried rituximab-
1b4mDTPA solution 
 
 
Fig. 26. ATR/FTIR spectrum for the lutetium chelated freeze dried rituximab-
1b4mDTPA solution 
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Fig. 27. ATR/FTIR spectrum for the yttrium chelated freeze dried rituximab-
1b4mDTPA solution 
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DISCUSSION 
 
The use of TMAs for treatment of lymphomas is already widespread worldwide. There 
is a broad range of TMAs that are currently on the market or in research for use on 
NHLs. Among all those, rituximab continues to dominate the market significantly. 
Compared to the newer generation of TMAs for lymphoma treatment, rituximab is rel-
atively less expensive and more accessible even in resource-poor countries. Also, 
rituximab is a chimeric TMA. In the area of radioimmunotherapy, all TMAs that have 
so far been registered for use on patients with lymphomas are murine and they expose 
treated patients to more adverse reactions and HAMA development. In addition, stud-
ies of this kind continue to attract huge interest from many researchers and the infor-
mation base of radioimmunotherapy using rituximab immunoconjugates continues tre-
mendously. These reasons and the fact that rituximab is already registered in most 
countries, already used as an adjunct with radioimmunotherapy of NHLs, and has an 
established efficacy and safety profile, led to the decision the decision to use rituximab 
for this study. With an optimized protocol, radiopharmacies would be capable of pro-
ducing rituximab-1b4m radiopharmaceutical kits in their own countries using locally 
available rituximab commercial preparations.  
The commercial rituximab product contains, apart from rituximab, excipients such as 
tween-80 and citrate buffer (“MabThera, INN-rituximab - WC500025821.pdf,” n. d.). 
The rituximab had to be purified from these excipients so as to avert any potential 
interference with freeze drying, conjugation or chelation processes. Common antibody 
purification methods include dialysis, gel filtration, ultrafiltration, etc. (Liu et al., 2010). 
Ultrafiltration was used because it is easy to set up, inexpensive, fast, efficient and 
reliable. Using the 30kDa millipore ultrafilters, antibody light chains and other lower-
than-30kDa molecules in the rituximab commercial product were sieved through the 
ultrafilters into the ultrafiltrate as the higher molecular weight rituximab whole TMA 
was retained. However, ultrafiltration has the possibility of increasing protein aggrega-
tion (Vázquez-Rey and Lang, 2011), structural changes and protein degradation due 
to the forces involved and also through antibody-antibody and/or antibody-membrane 
interactions. To minimize such potential adverse effects to the TMA, the least possible 
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number of ultrafiltration cycles were used. The necessary number of cycles were de-
termined by performing a trial purification run of the rituximab commercial product with 
serial measurements of protein concentration in the ultra-filtrate by UV-VIS spectro-
photometry at 280nm wavelength. The cycle number after which the ultrafiltrate pro-
tein concentration became undetectable was considered the least necessary and all 
other TMA purification runs were performed using the least necessary cycles. To re-
cover the purified rituximab from the ultrafilter membranes, the ultrafilters were in-
verted and centrifuged. For the recovery, a one-hour centrifugation cycle was found to 
be adequate. 
In the end, it was important to establish whether the purification was successful. This 
was achieved by comparing the protein purity of the impure commercial rituximab 
product and the purified product by their SEC spectra. The picture is as shown in Fig-
ure 20 below. 
 
Fig. 28. Confirmation of effectiveness of purification of rituximab commercial               for-
mulation by comparison between SEC spectra of non-purified and purified samples 
 
It can be seen that the small peaks attributed to 6th and 10th fractions were               
completely eliminated. Any minor impurities associated to such peaks were, therefore, 
successfully got rid of by ultrafiltration. Also, the 5th fraction was no longer the domi-
nant peak following purification as it was decreased by 58% (from 0.43 mg/ml to 
0.18mg/ml). In the impure sample, the desired whole TMA collected in the 4th fraction 
consisted of 35% of the expected 1mg protein in the sample. In contrast, the purified 
sample contained almost 60% of its protein content as the whole antibody (4th frac-
tion). Peaks of 5th fraction may be attributable to antibody fragments larger than could 
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be filtered through the 30kDa millipore filter membranes, such as Fc and F (ab2)' frag-
ments. Inasmuch as the 4th fraction is expected to carry some antibody aggregates 
formed from the antibody-antibody and antibody-membrane interactions during cen-
trifugation at 5000 rpm, significant amounts could have been collected in 2nd, 3rd or 
even 1st fractions. Testing for antibody aggregates at 410 nm wavelength by UV-VIS 
spectrophotometry revealed that the 3rd fractions in both spectra contained the     high-
est amounts of aggregates while they were undetectable in the 4th fractions. The ob-
servation was in agreement with the observations made by other authors (Katarina S. 
2014). It is evident from Figure 20 above that the purification process was   adequate 
considering the increase in the higher molecular weight peak height accompanied with 
a decrease in the lower molecular weight peak heights. After the successful purifica-
tion, we deemed the antibody as ready for conjugation with the bifunctional chelating 
agent 1b4mDTPA. 
The freeze drying protocol that we wanted to use was a two-day protocol and it was 
the key point of our investigation. Many authors have already used the three-day 
freeze drying method for studying kit formulations containing rituximab-1b4mDTPA 
(Gjorgieva Ackova et al., 2014). In this work we wanted to compare the three-day 
protocol with the new two-day protocol that can potentially provide faster time of freeze 
drying, higher stability of the final product, same quality and good radiolabeling yield 
with either yttrium-90 or lutetium-177. 
In this study, the new freeze drying protocol was tested with the non-conjugated         
antibody with the expectation that the findings obtained therefrom would provide         
information on the suitability of the protocol for freeze drying of the immunoconjugate. 
The non-conjugated antibody was also freeze dried via the three-day protocol. The 
products emanating from the two freeze drying protocols were compared in terms of 
their cake appearance, SEC spectra and UV-VIS spectra. A comparison of the above 
parameters between the freeze dried products and the non-freeze dried rituximab     
solution was also made so as to determine the effect of each protocol on the rituximab. 
During freeze drying, the antibody molecule is expected to undergo some reversible 
unfolding in the dry product (Carpenter et al., 2002). A well freeze dried product en-
sures that the antibody folds back to its biologically active tertiary and quaternary struc-
tures upon its reconstitution into its solution of final usage. We used a comparison of 
the clarity, FTIR spectra and SEC spectra of the solutions of reconstituted freeze dried 
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products with the clarity, FTIR spectra and SEC spectra of the non-freeze dried prod-
ucts to determine if our protocol was superior, inferior or non-inferior to the previously 
used three-day protocol. As demonstrated in Figures 7, 8 (above), 29 and 31 (below), 
our two-day free drying protocol was comparable to the previously studied three-day 
protocol.   
 
 
Figure 29. Comparison of the SEC spectra between the commercial rituximab product, 
3-day freeze dried rituximab and 2-day freeze dried rituximab 
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Figure 30. Comparison of the ATR/FTIR spectra of the powders from the 3-day freeze 
drying protocol (red) versus that of the 2-day freeze drying protocol (blue). 
 
 
 
Figure 31. Comparison of the ATR/FTIR spectra of the reconstituted freeze dried          
rituximab powders (red – 2 day protocol, blue – 3 day protocol), commercial rituximab 
solution (green) and purified/ultra-filtered rituximab (black). 
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Conjugation of rituximab with an appropriate chelator for lutetium or yttrium was         
essential as rituximab hardly chelates these metals directly (Liu, 2008). Since this kit 
preparation is designed for post-labeling, conjugation of the antibody with the chelator 
into an immunoconjugate prior to radiolabeling was done.  
The choice for the post-labeling approach is informed by the fact that the conjugation 
chemistry is more controllable and more suitable for kit formulation (Tolmachev et al., 
2014). An already established conjugation protocol was used (Thakral et al., 2014). In 
previous studies (Gjorgieva Ackova et al., 2015), the conjugation protocol yielded. Im-
munoconjugates with an average of 6 chelator groups attached to each antibody mol-
ecule.  
The desired number of chelator groups per antibody molecule is considered to be 
about 5 or 6 (Cooper et al., 2011) (Cooper et al., 2012). Less than 4 chelator groups 
per antibody is more likely to produce less than effective specific activity of the radio-
pharmaceutical, whereas the affinity of the radiopharmaceutical to the receptor site is 
less than optimal if the chelator groups per antibody molecule is above 8, due to steric 
hindrance from the bulky chelator groups.  
The team that used a similar conjugation protocol to our protocol confirmed an            
average chelator number of 6 per antibody molecule by using MALDI-TOF mass spec-
trometry (Gjorgieva   Ackova et al., 2014). 
The purification of the immunoconjugate is an important step to obtain the pure prod-
uct for labeling and to eliminate excess of the ligand and damaged and fragmented     
antibody.  
Because we used molar ratio of antibody-to-chelator of 1:20, the presence of excess 
chelator is expected.  
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Figure 32. Comparison of the SEC spectra between the non-purified (above) and   pu-
rified (below) immunoconjugate solutions 
 
For the determination of the final concentration that we used for the kit formulation we 
needed to calculate the concentration of the immunoconjugate after purification. The 
minimum desired immunoconjugate concentration for the kit formulation was 1mg/ml. 
After purification using ultra-filtration we determined the concentration measuring the 
samples of each fraction with UV-VIS spectrophotometry. 
The final concentration was 6.85mg/ml in 2ml. This product was diluted accordingly to 
a 13.7ml 1mg/ml solution that corresponded to our need. 
The selected protocol for freeze drying of the immunoconjugate was the two-days pro-
tocol as described in the methods section above. 
The obtained results as presented in the results section confirm that this protocol is 
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also appropriate for the freeze drying of the immunoconjugate. 
 
 
Fig. 33. Comparison by visual inspection of the appearance of the freeze dried cakes 
of rituximab by 3-day freeze drying protocol (left), rituximab by 2-day freeze drying 
protocol (middle) and immunoconjugate by 2-day freeze drying protocol (right). 
 
The cold labeling was performed by chelation of the reconstituted immunoconjugate 
solution with LuCl3 or YCl3 using the protocol described in the methods section above. 
The goal of cold labeling is to use the same amounts of the Lu and Y as are used in 
their respective radioactive isotopes for the delivery of clinical therapeutic radio-activ-
ities (Kam et al., 2012) (“Zevalin_Package_Insert.pdf,” n.d.). 
 
 
Fig. 34. Comparison between the SEC spectra of the ‘cold’ labeled solutions of Y-
immunoconjugate (left) and Lu-immunoconjugate (right). 
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As seen from the methods section above, we performed many manipulations on the 
antibody, starting from its approved commercial product up to the final metal chelated 
solutions. For that reason, we considered it of vital importance to investigate the        
molecular structures of all our products and more importantly, to compare the             
molecular structures of the processed products to the unprocessed products at each 
step. Since infrared spectroscopy is able to give us structural information (Barth, 
2007), the FTIR spectra of the products were compared. 
As seen from the results above, the two- day protocol yields an FTIR spectrum of the 
freeze dried powder that is similar to the spectrum obtained from the three-day      pro-
tocol that was previously studied. This finding demonstrates the possibility of achieving 
similar results as the three-day protocol with a shortened processing time. 
Large proteins such as antibodies adopt complex structures when they are in their 
aqueous solutions. This results from the complex interactions that exist amongst the 
different amino acid residues and within the antibody molecules and between the 
amino acid residues and the surrounding water molecules. Freeze drying removes 
most of the free water in the environment of the antibody, leaving only the tightly bound 
water that is essential for avoiding plastic deformation of the protein molecules. From 
literature, it has been found that different freeze drying protocols may yield different 
protein molecular structures in the solid form as evidenced from FTIR spectra or       
Raman spectra. However, when the products of the different freeze drying protocols 
are reconstituted, the proteins relax back into their original secondary, tertiary and 
quaternary structures. In such cases, the FTIR spectra of the different liquid samples 
will be superimposable regardless of the spectra of their respective solid samples. 
When results of that kind are obtained, the different freeze drying protocols are           
adjudged to be suitable for the particular protein formulation. However, some freeze 
drying protocols may yield products that after reconstitution in aqueous solvents 
demonstrate FTIR spectra that are different from the spectrum of the parent product. 
Such freeze drying protocols are considered unacceptable on the account that they 
induce irreversible structural deformations on the antibody molecules and as such, 
they would be highly expected to impair the in vivo antigen binding of the antibody. In 
consideration of the foregoing, the structural integrity of the product after reconstitution 
and after metal chelation was of greater importance than that of the freeze dried solid 
immunoconjugate. 
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As shown from the results above, the FTIR spectra of the liquid samples of the com-
mercial rituximab product, the purified rituximab, the freeze dried rituximab, the non-
freeze dried immunoconjugate, the freeze dried immunoconjugate and the metal che-
lated products are superimposable. The observation that the FTIR spectra of all the 
products are superimposable provides an indication that the molecular structures of 
the products were not adversely affected by the manipulations. Such information is of 
paramount importance since the in vivo antigen binding of the radiolabeled antibody 
relies hugely on its structural integrity.  
For the liquid FTIR spectra to be superimposable, not only the primary structures but 
also the secondary structures of the different antibody molecules need to be similar. 
Since this was achieved between the samples obtained with the three-day process of 
freeze drying in comparison with the products of the new two-day protocol, we were 
able to demonstrate that the shorter freeze drying protocol yields similar product char-
acteristics to the already established three-day protocol. 
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CONCLUSION 
 
The study confirmed that the purification method of ultrafiltration that had been used 
previously for similar studies was still suitable for purification of rituximab antibody 
form its excipients in MabThera without significant damage to the antibody. The         
purification method is therefore recommended for use in similar experiments. 
Inasmuch as the conjugation protocol yielded the acceptable 4 – 8 chelator groups 
per antibody molecule, there was fragmentation of the antibody of up to 25% resulting 
into a yield of 75% for the conjugation step. Such antibody losses have a significant 
impact on the yield and cost of production of the immunoconjugate. Therefore, more 
studies for optimization of the conjugation protocol are recommended.  
The freeze drying protocols of two days and three days yield products of similar quality. 
None of the freeze drying protocols produced detectable fragments. The cake             
appearance, reconstitution times and opacity on reconstitution were similar, demon-
strating that the two freeze drying protocols yield products of similar quality.  
In the radiolabeling conditions that were used, at least 30% fragmentation of the im-
munoconjugate occurred. The conditions for lutetium labeling caused less fragmenta-
tion of the immunoconjugate than the conditions for yttrium labeling. Therefore, opti-
mization studies on the labeling protocol or introduction of a purification step post la-
beling are potentially beneficial. 
From this study, we conclude that the two-day freeze drying protocol is non-inferior to 
the three-day protocol. It may, in fact, be superior to the three-day protocol based on 
the time and energy saved.  More studies on the optimization and control of the critical 
freeze drying process parameters and the critical formulation attributes are also en-
couraged, as well as optimization of the conjugation and labeling protocols. Infor-
mation continues to be sought that can support further development of the rituximab-
1b4mDTPA kit radiopharmaceutical for NHL radioimmunotherapy. 
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